Salarius Pharmaceuticals (SLRX) Competitors $1.34 -0.01 (-0.74%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.34 0.00 (0.00%) As of 02/21/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends SLRX vs. RLMD, TSBX, EDSA, PBM, BFRI, AYTU, CYCN, CELZ, AIM, and DWTXShould you be buying Salarius Pharmaceuticals stock or one of its competitors? The main competitors of Salarius Pharmaceuticals include Relmada Therapeutics (RLMD), Turnstone Biologics (TSBX), Edesa Biotech (EDSA), Psyence Biomedical (PBM), Biofrontera (BFRI), Aytu BioPharma (AYTU), Cyclerion Therapeutics (CYCN), Creative Medical Technology (CELZ), AIM ImmunoTech (AIM), and Dogwood Therapeutics (DWTX). These companies are all part of the "pharmaceutical products" industry. Salarius Pharmaceuticals vs. Relmada Therapeutics Turnstone Biologics Edesa Biotech Psyence Biomedical Biofrontera Aytu BioPharma Cyclerion Therapeutics Creative Medical Technology AIM ImmunoTech Dogwood Therapeutics Salarius Pharmaceuticals (NASDAQ:SLRX) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, community ranking, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations. Does the MarketBeat Community prefer SLRX or RLMD? Salarius Pharmaceuticals received 9 more outperform votes than Relmada Therapeutics when rated by MarketBeat users. Likewise, 54.17% of users gave Salarius Pharmaceuticals an outperform vote while only 37.78% of users gave Relmada Therapeutics an outperform vote. CompanyUnderperformOutperformSalarius PharmaceuticalsOutperform Votes2654.17% Underperform Votes2245.83% Relmada TherapeuticsOutperform Votes1737.78% Underperform Votes2862.22% Do analysts prefer SLRX or RLMD? Relmada Therapeutics has a consensus target price of $4.25, suggesting a potential upside of 1,340.68%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Relmada Therapeutics is more favorable than Salarius Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Salarius Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Relmada Therapeutics 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has stronger valuation & earnings, SLRX or RLMD? Salarius Pharmaceuticals is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSalarius PharmaceuticalsN/AN/A-$12.54M-$8.17-0.16Relmada TherapeuticsN/AN/A-$98.79M-$2.87-0.10 Is SLRX or RLMD more profitable? Relmada Therapeutics' return on equity of -129.80% beat Salarius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Salarius PharmaceuticalsN/A -140.28% -105.76% Relmada Therapeutics N/A -129.80%-112.06% Which has more volatility and risk, SLRX or RLMD? Salarius Pharmaceuticals has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Do insiders & institutionals believe in SLRX or RLMD? 11.9% of Salarius Pharmaceuticals shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 1.4% of Salarius Pharmaceuticals shares are owned by insiders. Comparatively, 18.0% of Relmada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to SLRX or RLMD? In the previous week, Salarius Pharmaceuticals' average media sentiment score of 0.00 equaled Relmada Therapeutics'average media sentiment score. Company Overall Sentiment Salarius Pharmaceuticals Neutral Relmada Therapeutics Neutral SummaryRelmada Therapeutics beats Salarius Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Get Salarius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLRX vs. The Competition Export to ExcelMetricSalarius PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.14M$7.07B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-0.165.4725.4719.00Price / SalesN/A306.08447.5876.30Price / CashN/A65.6738.0134.83Price / Book0.126.717.644.62Net Income-$12.54M$138.33M$3.18B$245.85M7 Day Performance-17.28%-2.61%-1.99%-2.68%1 Month Performance-50.00%-2.32%-0.42%-2.19%1 Year Performance-70.04%-5.31%16.51%12.84% Salarius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLRXSalarius Pharmaceuticals0.5759 of 5 stars$1.34-0.7%N/A-70.6%$2.14MN/A-0.1620RLMDRelmada Therapeutics4.3054 of 5 stars$0.33+1.3%$4.25+1,176.7%-94.8%$10.04MN/A-0.1210Gap DownTSBXTurnstone Biologics1.529 of 5 stars$0.41+6.0%$0.45+8.8%-84.1%$9.56M$19.31M-0.1382EDSAEdesa Biotech2.3377 of 5 stars$2.69-17.2%$21.00+680.7%-53.9%$9.33MN/A-1.3920Earnings ReportHigh Trading VolumePBMPsyence BiomedicalN/A$1.40+9.0%N/A-97.0%$9.21MN/A0.00N/ABFRIBiofrontera2.6469 of 5 stars$1.18+0.9%$7.00+493.2%+13.6%$9.14M$35.36M-0.5270News CoveragePositive NewsAYTUAytu BioPharma1.0241 of 5 stars$1.39+0.4%N/A-55.0%$8.52M$81M-1.13160High Trading VolumeCYCNCyclerion Therapeutics0.7879 of 5 stars$3.12+3.0%N/A-1.1%$8.46M$1.62M0.0030CELZCreative Medical Technology0.8936 of 5 stars$4.74+3.3%N/A+28.0%$8.30M$10,000.00-1.255Gap DownHigh Trading VolumeAIMAIM ImmunoTech1.7411 of 5 stars$0.13-6.9%$2.75+2,031.8%-67.1%$8.23M$200,000.00-0.2720High Trading VolumeDWTXDogwood TherapeuticsN/A$6.13-8.6%N/AN/A$8.15MN/A-0.945 Related Companies and Tools Related Companies RLMD Competitors TSBX Competitors EDSA Competitors PBM Competitors BFRI Competitors AYTU Competitors CYCN Competitors CELZ Competitors AIM Competitors DWTX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SLRX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Salarius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
